PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerAntonino Glaviano, Alan Prem Kumar, William Jacot et al.|Molecular Cancer|2023Cited by 1.9k
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S. Davids, Alexey V. Danilov, Danielle M. Brander et al.|Blood Advances|2024Cited by 9